Senegalese TNBC Cohort Shows a Distinct Inflammatory Blood Signature
Triple-negative breast cancer has long presented a difficult diagnostic and therapeutic problem because it behaves aggressively while offering fewer treatment targets than hormone receptor-positive disease. In a Senegalese cohort, routine blood tests captured a measurable systemic signature at the moment of diagnosis, before treatment could alter the biology. The pattern was strongest in triple-negative breast cancer, where neutrophils, C-reactive protein, and several derived inflammatory ratios moved in the same direction. Even in a setting where advanced molecular profiling may not be universally available, that kind of signal matters because it comes from assays already embedded in everyday hospital practice.
The study examined 120 women at Dalal Jamm Hospital in Dakar between July 2022 and February 2024. Forty had TNBC, 40 had hormone-dependent breast cancer, and 40 were healthy controls. Blood was drawn before any therapy began, which preserved the baseline inflammatory state rather than a treatment-altered version of it. Complete blood counts and CRP were measured, then the neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, and platelet-to-lymphocyte ratio were calculated to test whether inexpensive hematologic markers could separate disease groups.
Neutrophils, CRP, and Derived Ratios Separated TNBC From Healthy Controls
The clearest divergence appeared between TNBC and healthy participants. Women with TNBC had higher neutrophil counts, higher C-reactive protein, higher NLR, and higher MLR, alongside lower lymphocyte and basophil percentages. Those shifts point toward a systemic inflammatory state paired with relative immune suppression, a combination that fits the biology of aggressive tumors. In practical terms, the tumor appears to be operating in an environment where innate inflammatory signals are amplified while adaptive immune counterweight is diminished.
One result stood out sharply: an NLR greater than 1.12 showed strong discriminatory ability, with an area under the curve of 0.847, sensitivity of 90%, and specificity of 65%. That is not a trivial separation for a low-cost marker derived from a standard blood count. For a clinician working in a resource-limited environment, a marker with high sensitivity can help flag patients whose inflammatory profile deserves closer attention, even if the test cannot stand alone as a diagnostic tool.
The biology behind the pattern is plausible. Neutrophil predominance often tracks with tumor-promoting inflammation, while lymphocyte depletion can reflect weakened antitumor surveillance. CRP adds another layer, functioning as a systemic readout of inflammatory signaling that may mirror tumor burden or host response. When those elements move together, they suggest more than random hematologic noise.
Hormone-Dependent Disease Shared Some Features, but TNBC Retained the Strongest Signal
The comparison with hormone-dependent breast cancer was more restrained. Differences between TNBC and hormone-dependent disease were less pronounced overall, with the most evident separation emerging for CRP and basophil levels. This is clinically interesting because it suggests that some inflammatory abnormalities may cut across breast cancer subtypes, while others are more tightly linked to the triple-negative phenotype. TNBC therefore may not be the only breast cancer subtype associated with systemic inflammation, but it appears to carry a more intense and diagnostically useful signature.
Basophil findings deserve attention even though they are less familiar in oncology practice. A reduction in basophil percentage may reflect broader immune remodeling rather than a direct tumor effect. In a disease as biologically aggressive as TNBC, even small shifts in leukocyte subtypes can be a clue that the host-tumor interaction is already altered at presentation.
Multivariate Analysis Kept NLR, CRP, and Neutrophils in the Frame
Multivariate analysis confirmed independent associations between elevated NLR, CRP, and neutrophils and TNBC. This matters because it reduces the chance that the findings simply reflect a single overlapping inflammatory variable. Instead, the data support a clustered hematologic phenotype that persists after adjustment. For bedside use, that raises the possibility of combining routine markers rather than depending on any one value in isolation.
A simple blood count does not replace pathology, imaging, or receptor testing. It can, however, sharpen triage when resources are constrained or when rapid risk stratification is needed before a full diagnostic workup is complete. In low-resource settings, this kind of biomarker strategy is especially relevant because the test is inexpensive, repeatable, and already familiar to clinicians. The threshold used here, NLR greater than 1.12, is also strikingly low, which suggests that even modest inflammatory shifts may carry meaning in this population.
Why This Matters for Early Stratification in Low-Resource Settings
The broader value of this study lies in its setting as much as in its numbers. Senegalese patients with TNBC may face delays in access to advanced molecular tools, and that reality makes simple biomarkers more attractive. If confirmed in larger cohorts, these inflammatory indices could help identify patients at diagnosis who are more likely to harbor biologically aggressive disease. They could also complement existing clinical assessment rather than compete with it.
This is not yet a basis for treatment change. The cohort was cross-sectional, so it cannot show whether the inflammatory profile predicts survival, recurrence, or treatment response. It also cannot establish whether the elevated inflammatory markers are driving the cancer phenotype or simply reflecting it. Still, the direction of the findings is coherent: TNBC presents with a measurable systemic inflammatory footprint that is larger than the one seen in healthy controls and, in some respects, distinct from hormone-dependent disease.
A practical next step would be to test whether these markers retain value in longitudinal follow-up, particularly after surgery, chemotherapy, or systemic therapy. It would also be useful to determine whether the same threshold holds across other African cohorts or whether local population factors alter the cutoffs. For now, the study leaves a specific clinical impression: in this Senegalese group, the blood count was not merely routine lab work. It carried a signal that tracked with the biology of aggressive breast cancer, and that signal was strong enough to measure before treatment ever began.